Timber Pharmaceuticals's net income is $-15M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2023
Trailing 12 months ending Jun 2023
Loading...
Loading...
Timber Pharmaceuticals (TMBR) currently reports a net income of $-15M as of June 2023. That compares with $-18M in the prior-year period — up 18.3% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Timber Pharmaceuticals's net income history and peer comparisons.
Timber Pharmaceuticals's net income increased from $-18M to $-15M — a 18.3% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Timber Pharmaceuticals's net income of $-15M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Timber Pharmaceuticals reported $-15M in net income as of June 2023. That compares with $-18M in the prior-year period — up 18.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-15M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Timber Pharmaceuticals, and consider following TMBR for alerts when major investors trade the stock.